N/A Completed N=114 Treatment

A Post-Market Study of the AMS AdVance™ Male Sling System for the Treatment of Male Stress Urinary Incontinence

Stress Urinary Incontinence

Source: ClinicalTrials.gov NCT00998790 ↗

Enrolled (actual)

114

Serious AEs

23.0%

Results posted

Oct 2018

Primary outcomePrimary: Change in 1-hour Pad Weight Test From Baseline to 24 Month Follow-up — 48.7; 6.6 grams

Summary

A prospective, multi-center study of the AdVance Male Sling for Stress Urinary Incontinence. The purpose of this study is to obtain surgical technique data for use in physician education and training and to collect early clinical outcomes data for future publication. This study is not designed to statistically demonstrate safety and efficacy of the device.

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in 1-hour Pad Weight Test From Baseline to 24 Month Follow-up	48.7; 6.6	—
PRIMARY Change in 24-hour Pad Weight Test From Baseline to 24 Month Follow-up	113.9; 45.0	—
PRIMARY Percentage of Subjects in Each Range of Pads Per Day Use	80.6; 12.9; 6.5; 0; 0; 0	—
PRIMARY Percentage of Subjects in Each Range of Pads Per Day Use	80.6; 12.9; 6.5; 0; 0; 0	—
SECONDARY To Evaluate Patient Quality of Life	55.9; 85.6; 15.5; 7.3	—

Eligibility Criteria

Inclusion Criteria

The subject has agreed to be implanted with the AMS AdVance Male Sling System.
The subject is willing and able to give valid informed consent.
The subject is ≥40 years of age.
The subject has confirmed stress urinary incontinence for at least 6 months and uses no more than 8 pads per day for incontinence management and has less than 250 grams on the 24-hour pad weight test.
The subject has any of the following: an observable degree of incontinence during stress related activities, more than one pad is used in a 24 hour period, has more than two episodes of incontinence per day.
Internal sphincter contractility confirmed by endoscopic view.
The subject's primary etiology is TUR, TURP, or radical prostatectomy.
Pre-existing urological conditions, other than incontinence have been treated and are under control.
The subject is willing and able to return for follow-up evaluations and questionnaire completion according to the study protocol.
The subject is a good surgical candidate.

Exclusion Criteria

The subject has a neurogenic bladder condition that is not treatable or controllable by pharmacological or alternative methods.
The subject has a post-void residual ≥ 100 cc.
The subject has detrusor-external sphincter dyssynergia.
The subject has a urinary tract infection (UTI).
The subject was treated with pelvic radiation within the last 6 months.
The subject currently has an inflatable penile prosthesis.
The subject self-catheterizes.
The subject has symptomatic or unstable bladder neck structure disease.
The subject has a history of urethral strictures that may require repetitive instrumentation.
The subject has previously had a urethral Sling System, an AMS Sphincter 800™, or any implanted device for the treatment of urinary incontinence (not including bulking agents).
The subject has a history of connective tissue or autoimmune conditions.
The subject has a compromised immune system.
The subject has renal insufficiency, and upper and/or lower urinary tract relative obstruction.
The subject's reading level is judged inadequate for reading and understanding the quality of life questionnaires and other study materials.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00998790). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.